PT3205720T - Vetor de expressão de car e células t que expressam car - Google Patents
Vetor de expressão de car e células t que expressam carInfo
- Publication number
- PT3205720T PT3205720T PT158494161T PT15849416T PT3205720T PT 3205720 T PT3205720 T PT 3205720T PT 158494161 T PT158494161 T PT 158494161T PT 15849416 T PT15849416 T PT 15849416T PT 3205720 T PT3205720 T PT 3205720T
- Authority
- PT
- Portugal
- Prior art keywords
- car
- expressing
- cells
- expression vector
- car expression
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464442—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014208200 | 2014-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3205720T true PT3205720T (pt) | 2019-10-28 |
Family
ID=55652864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT158494161T PT3205720T (pt) | 2014-10-09 | 2015-10-06 | Vetor de expressão de car e células t que expressam car |
PT191961960T PT3597742T (pt) | 2014-10-09 | 2015-10-06 | Vetor de expressão de car e células t que expressam car |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191961960T PT3597742T (pt) | 2014-10-09 | 2015-10-06 | Vetor de expressão de car e células t que expressam car |
Country Status (28)
Country | Link |
---|---|
US (3) | US10316102B2 (pt) |
EP (2) | EP3205720B1 (pt) |
JP (5) | JP6161098B2 (pt) |
KR (1) | KR101890638B1 (pt) |
CN (1) | CN107109421B (pt) |
AU (1) | AU2015329444B2 (pt) |
BR (1) | BR112017006710B1 (pt) |
CA (1) | CA2962375C (pt) |
CY (1) | CY1122324T1 (pt) |
DK (2) | DK3597742T3 (pt) |
ES (2) | ES2927366T3 (pt) |
HR (2) | HRP20221211T1 (pt) |
HU (2) | HUE046710T2 (pt) |
IL (1) | IL251504B (pt) |
LT (2) | LT3205720T (pt) |
MX (1) | MX358472B (pt) |
MY (1) | MY167722A (pt) |
NZ (1) | NZ730382A (pt) |
PH (1) | PH12017500596A1 (pt) |
PL (2) | PL3597742T3 (pt) |
PT (2) | PT3205720T (pt) |
RS (2) | RS63601B1 (pt) |
RU (1) | RU2670147C1 (pt) |
SG (1) | SG11201702391RA (pt) |
SI (2) | SI3597742T1 (pt) |
TW (1) | TWI688651B (pt) |
WO (1) | WO2016056228A1 (pt) |
ZA (1) | ZA201701968B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201702391RA (en) * | 2014-10-09 | 2017-04-27 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
EP3416686A1 (en) | 2016-02-16 | 2018-12-26 | Dana Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
AU2017235116B2 (en) | 2016-03-17 | 2019-11-07 | Yamaguchi University | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
CA3048312A1 (en) * | 2017-01-01 | 2018-07-05 | Chi-Yu Gregory Lee | Rp215 chimeric antigen receptor construct and methods of making and using same |
CN110177876B (zh) * | 2017-01-10 | 2023-03-31 | 国立大学法人山口大学 | 抗gpc3抗体 |
RU2770002C2 (ru) * | 2017-03-27 | 2022-04-14 | Нойл-Иммьюн Байотек, Инк. | Химерный антигенный рецептор |
CN108484777B (zh) * | 2017-03-31 | 2022-07-12 | 李吉祐 | 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 |
EP3695846B1 (en) * | 2017-10-10 | 2023-11-29 | Yamaguchi University | Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells |
WO2019124468A1 (ja) | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 |
EA202091566A1 (ru) * | 2017-12-27 | 2020-09-18 | Такеда Фармасьютикал Компани Лимитед | Содержащая нуклеиновую кислоту липидная наночастица и ее применение |
CN108641001A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 结肠癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108641000A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 肝癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108659133A (zh) * | 2018-04-26 | 2018-10-16 | 上海怡豪生物科技有限公司 | 肺癌的双靶点car-t治疗载体及其构建方法和应用 |
CN112154204A (zh) * | 2018-05-15 | 2020-12-29 | 科济生物医药(上海)有限公司 | 基因工程化的细胞及应用 |
KR20190141511A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 녹십자랩셀 | 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포 |
CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术(广州)有限公司 | Shp-1敲除的t细胞及其构建方法 |
WO2020017479A1 (ja) | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗gpc3一本鎖抗体を含むcar |
CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
TW202016295A (zh) * | 2018-08-31 | 2020-05-01 | 日商諾伊爾免疫生物科技股份有限公司 | Car表現t細胞及car表現載體 |
WO2020057641A1 (zh) * | 2018-09-20 | 2020-03-26 | 科济生物医药(上海)有限公司 | 表达有趋化因子的细胞及用途 |
WO2020077356A1 (en) * | 2018-10-12 | 2020-04-16 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
CN109504660B (zh) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
AU2020235395A1 (en) * | 2019-03-08 | 2021-09-02 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR |
CN112080526A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 表达il-7和car的表达载体及免疫细胞 |
CN112080525A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 一种改良型嵌合抗原受体t细胞的制备 |
JP2021016371A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社東芝 | Car−t細胞の製造方法、核酸導入キャリア及びキット |
MX2022004962A (es) | 2019-10-28 | 2022-08-16 | Noile Immune Biotech Inc | Fármaco para el tratamiento del cáncer, combinación de fármacos, composición de fármacos, célula de respuesta inmune, vehículo de administración de ácidos nucleicos y producto. |
CN110922490B (zh) * | 2019-12-05 | 2023-03-03 | 浙江启新生物技术有限公司 | 分泌白介素7和趋化因子21的car表达载体及应用 |
CN115427451A (zh) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途 |
CN113528483A (zh) * | 2020-04-22 | 2021-10-22 | 复星凯特生物科技有限公司 | Shp2特异性失活突变蛋白及其在car-t治疗中应用 |
GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
CN115885038A (zh) | 2020-06-17 | 2023-03-31 | 国立大学法人京都大学 | 表达嵌合抗原受体的免疫活性细胞 |
KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
CN116782937A (zh) | 2020-12-10 | 2023-09-19 | 优特力克斯有限公司 | 抗pd-1抗体及其用途 |
CN114717203B (zh) * | 2020-12-22 | 2023-06-27 | 广东东阳光药业有限公司 | 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途 |
CN114716548A (zh) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
KR102568745B1 (ko) | 2021-05-18 | 2023-08-24 | 주식회사 바이오솔루션 | 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법 |
AU2022318416A1 (en) | 2021-07-29 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
CN113913385A (zh) * | 2021-09-01 | 2022-01-11 | 苏州璞惠卓越生物科技有限公司 | 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途 |
CN113921082B (zh) * | 2021-10-27 | 2023-04-07 | 云舟生物科技(广州)股份有限公司 | 基因搜索权重调整方法、计算机存储介质及电子设备 |
WO2023081455A2 (en) * | 2021-11-08 | 2023-05-11 | Memorial Sloan-Kettering Cancer Center | Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same |
WO2023223292A1 (en) * | 2022-05-20 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Methods of producing engineered immune cells |
US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
CN115505601B (zh) * | 2022-10-17 | 2024-05-28 | 深圳市先康达生命科学有限公司 | 一种两级SynNotch逻辑调控结构及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857318A (ja) * | 1981-10-01 | 1983-04-05 | Nippon Koutai Kenkyusho:Kk | 癌細胞障害性リンパ球の製造法 |
JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Cd19特異的再指向免疫細胞 |
KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
BRPI0920679A2 (pt) * | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
CN107699585A (zh) | 2010-12-09 | 2018-02-16 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
WO2012082841A2 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
US9266960B2 (en) | 2011-04-08 | 2016-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
ES2795023T3 (es) * | 2011-09-16 | 2020-11-20 | Baylor College Medicine | Reconocimiento específico del microambiente tumoral mediante el uso de células NKT manipuladas |
KR101956751B1 (ko) | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
US9447194B2 (en) * | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
BR112014020502A2 (pt) * | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
CN102625373A (zh) | 2012-02-22 | 2012-08-01 | 中兴通讯股份有限公司 | 一种智能载波管理方法及装置 |
SG11201702391RA (en) * | 2014-10-09 | 2017-04-27 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
-
2015
- 2015-10-06 SG SG11201702391RA patent/SG11201702391RA/en unknown
- 2015-10-06 PL PL19196196.0T patent/PL3597742T3/pl unknown
- 2015-10-06 LT LT15849416T patent/LT3205720T/lt unknown
- 2015-10-06 HR HRP20221211TT patent/HRP20221211T1/hr unknown
- 2015-10-06 WO PCT/JP2015/005080 patent/WO2016056228A1/ja active Application Filing
- 2015-10-06 KR KR1020177009895A patent/KR101890638B1/ko active IP Right Grant
- 2015-10-06 SI SI201531887T patent/SI3597742T1/sl unknown
- 2015-10-06 SI SI201530950T patent/SI3205720T1/sl unknown
- 2015-10-06 MX MX2017004393A patent/MX358472B/es active IP Right Grant
- 2015-10-06 RS RS20220895A patent/RS63601B1/sr unknown
- 2015-10-06 PT PT158494161T patent/PT3205720T/pt unknown
- 2015-10-06 JP JP2016552830A patent/JP6161098B2/ja active Active
- 2015-10-06 EP EP15849416.1A patent/EP3205720B1/en active Active
- 2015-10-06 DK DK19196196.0T patent/DK3597742T3/da active
- 2015-10-06 EP EP19196196.0A patent/EP3597742B1/en active Active
- 2015-10-06 CN CN201580053922.1A patent/CN107109421B/zh active Active
- 2015-10-06 HU HUE15849416A patent/HUE046710T2/hu unknown
- 2015-10-06 ES ES19196196T patent/ES2927366T3/es active Active
- 2015-10-06 DK DK15849416.1T patent/DK3205720T3/da active
- 2015-10-06 NZ NZ730382A patent/NZ730382A/en unknown
- 2015-10-06 MY MYPI2017701137A patent/MY167722A/en unknown
- 2015-10-06 RU RU2017114545A patent/RU2670147C1/ru active
- 2015-10-06 BR BR112017006710A patent/BR112017006710B1/pt active IP Right Grant
- 2015-10-06 HU HUE19196196A patent/HUE060047T2/hu unknown
- 2015-10-06 RS RSP20191315 patent/RS59441B1/sr unknown
- 2015-10-06 LT LTEP19196196.0T patent/LT3597742T/lt unknown
- 2015-10-06 ES ES15849416T patent/ES2751945T3/es active Active
- 2015-10-06 AU AU2015329444A patent/AU2015329444B2/en active Active
- 2015-10-06 CA CA2962375A patent/CA2962375C/en active Active
- 2015-10-06 US US15/513,870 patent/US10316102B2/en active Active
- 2015-10-06 PL PL15849416T patent/PL3205720T3/pl unknown
- 2015-10-06 PT PT191961960T patent/PT3597742T/pt unknown
- 2015-10-08 TW TW104133272A patent/TWI688651B/zh active
-
2017
- 2017-03-22 ZA ZA2017/01968A patent/ZA201701968B/en unknown
- 2017-03-31 PH PH12017500596A patent/PH12017500596A1/en unknown
- 2017-04-02 IL IL251504A patent/IL251504B/en active IP Right Grant
- 2017-06-06 JP JP2017111736A patent/JP6683990B2/ja active Active
-
2019
- 2019-05-06 US US16/404,165 patent/US10906984B2/en active Active
- 2019-10-11 HR HRP20191839TT patent/HRP20191839T1/hr unknown
- 2019-11-26 CY CY20191101239T patent/CY1122324T1/el unknown
-
2020
- 2020-03-19 JP JP2020048623A patent/JP7008350B2/ja active Active
- 2020-12-23 US US17/133,286 patent/US20210253726A1/en active Pending
-
2021
- 2021-12-28 JP JP2021213604A patent/JP7300763B2/ja active Active
-
2023
- 2023-06-13 JP JP2023097065A patent/JP2023116674A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251504B (en) | car expression vector and t cells expressing car | |
IL274903A (en) | cell | |
HK1231471A1 (zh) | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 | |
IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
GB201403684D0 (en) | Vector | |
GB201616238D0 (en) | Modified T cells | |
PL3091590T3 (pl) | Ogniwo akumulatorowe zawierające element zapobiegający fałdowaniu | |
PL2952406T3 (pl) | Wózek i przyczepa | |
GB201408091D0 (en) | Methods and uses | |
HUE042287T2 (hu) | Lítium-kén cella | |
GB201604427D0 (en) | Modified cell | |
IL236273A0 (en) | Cells and battery organizers | |
GB201416086D0 (en) | Methods and uses | |
GB201416073D0 (en) | Methods and uses | |
GB201410934D0 (en) | T cell |